Breaking News, Financial News

Moderna Reports 3Q $3.6B Loss

Spikevax (COVID-19 vaccine) sales in the quarter were down 44% to $1.8 billion while R&D expenses increase 41% to $1.2 billion.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Moderna  3Q Revenues: $1.8 billion (-46%) 3Q Loss: $3.6 billion (earnings were $1.0 billion 3Q22) YTD Revenues: $4.0 billion (-72%) YTD Loss: $4.9 billion (earnings were $6.9 billion YTD22) Comments: Spikevax (COVID-19 vaccine) sales in the quarter were $1.8 billion, down 44% primarily driven by lower sales volume and partially offset by a higher average selling price.   The Company expects the launch of its RSV vaccine in 2024. Moderna has submitted marketing authorization applications g...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters